Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937937 · ClinicalTrials.gov registry record · Phase 2
Dinaciclib in Treating Patients With Stage IV Melanoma
A Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT00937937 is a Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 170-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00937937, a Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Dinaciclib
Study Locations (20)
California
- East Bay Radiation Oncology Center - Castro Valley
- Eden Hospital Medical Center - Castro Valley
- Valley Medical Oncology Consultants-Castro Valley - Castro Valley
- Bay Area Breast Surgeons Inc - Emeryville
- Valley Medical Oncology Consultants-Fremont - Fremont
- Contra Costa Regional Medical Center - Martinez
- El Camino Hospital - Mountain View
- Wilma Chan Highland Hospital - Oakland
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Tumor Institute - Oakland
- Hematology and Oncology Associates-Oakland - Oakland
- Tom K Lee Inc - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Valley Care Health System - Pleasanton - Pleasanton
- Valley Medical Oncology Consultants - Pleasanton
- Doctors Medical Center- JC Robinson Regional Cancer Center - San Pablo
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Rogers - Rogers
Alabama
- Providence Hospital - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-07-01 |
| Est. Completion | 2026-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937937
The ClinicalTrials.gov registry entry for NCT00937937 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (58% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Dinaciclib is the first listed.
NCT00937937 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00937937 about?
NCT00937937 is a clinical study titled "Dinaciclib in Treating Patients With Stage IV Melanoma". This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00937937?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-07-01. Estimated completion is 2026-03-19.
What conditions does trial NCT00937937 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Mucosal Melanoma, Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma.
What interventions are being tested in trial NCT00937937?
The interventions under investigation include: Dinaciclib (DRUG).
Who is sponsoring clinical trial NCT00937937?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00937937 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.